Trial Profile

Risk of Incident Immune-mediated Inflammatory Diseases (IMID) in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Baricitinib (Primary) ; Brodalumab (Primary) ; Guselkumab (Primary) ; Ixekizumab (Primary) ; Risankizumab (Primary) ; Sarilumab (Primary) ; Secukinumab (Primary) ; Upadacitinib (Primary) ; Vedolizumab (Primary) ; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Methotrexate; Tocilizumab; Tofacitinib; Ustekinumab
Indications Ankylosing spondylitis; Crohn's disease; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
Focus Therapeutic Use
Acronyms PROTECT-IMID

21 Apr 2023 Status changed from not yet recruiting to active, no longer recruiting.
31 Jan 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com